XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects

Inclusion Criteria

• •Age ≥18 years, male and female,
• •Confirmed as CD19-positive B cell lymphoma/leukemia by immunohistochemistry or flow cytometry
• •No effective treatment
• •Patients must have a measurable or evaluable disease at the time of enrollment.
• •Adequate organ system function including:
• •* ALT/AST \< 3 upper limit of normal; Total Bilirubin \< 2.5 upper limit of normal
• •* Creatinine \< 2 upper limit of normal
• •* Oxygen saturation ≥ 95%
• •* Left ventricular ejection fraction ≥ 40%
• •* Number of neutrophil ≥ 0.75×10\^9/L, number of platelet ≥ 50×10\^9/L
• •At least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy, monoclonal antibody therapy or other treatments)
• •No contraindications of peripheral blood apheresis
• •Female subjects in childbearing age, their serum or urine pregnancy test must be negative. All patients must agree to take effective contraceptive measures during the trial measures
• •ECOG score 0-2, expected survival ≥ 12 weeks